-
2
-
-
38449089313
-
The problem of transplanting the sensitized patient: Whose problem is it?
-
Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: Whose problem is it? Front Biosci 2008; 13: 1396.
-
(2008)
Front Biosci
, vol.13
, pp. 1396
-
-
Jackson, A.M.1
Zachary, A.A.2
-
3
-
-
0037184308
-
All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies
-
Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
-
(2002)
Transplantation
, vol.74
, pp. 1192
-
-
Lee, P.C.1
Terasaki, P.I.2
Takemoto, S.K.3
-
5
-
-
3042743987
-
National conference to assess antibody-mediated rejection in solid organ transplantation
-
Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
-
(2004)
Am J Transplant
, vol.4
, pp. 1033
-
-
Takemoto, S.K.1
Zeevi, A.2
Feng, S.3
-
6
-
-
47549105407
-
Rituximab and intravenous immune globulin for desensitization during renal transplantation
-
Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
-
(2008)
N Engl J Med
, vol.359
, pp. 242
-
-
Vo, A.1
Lukovsky, M.2
Toyoda, M.3
-
7
-
-
77951823581
-
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation
-
Vo A, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
-
(2010)
Transplantation
, vol.89
, pp. 1095
-
-
Vo, A.1
Peng, A.2
Toyoda, M.3
-
8
-
-
33644927503
-
Intravenous gammablobulin (IVIG):A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
-
Jordan SC, Vo AA, Peng A, et al. Intravenous gammablobulin (IVIG):A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
-
(2006)
Am J Transplant
, vol.6
, pp. 459
-
-
Jordan, S.C.1
Vo, A.A.2
Peng, A.3
-
9
-
-
0042838104
-
Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients
-
Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
-
(2003)
Transplantation
, vol.76
, pp. 631
-
-
Jordan, S.C.1
Vo, A.2
Bunnapradist, S.3
-
10
-
-
9644262465
-
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial
-
Jordan SC, Tyan DB, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial. J AmSoc Nephrol 2004; 15: 3256.
-
(2004)
J AmSoc Nephrol
, vol.15
, pp. 3256
-
-
Jordan, S.C.1
Tyan, D.B.2
Stablein, D.3
-
11
-
-
33644927503
-
Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
-
Jordan SC, Vo A, Peng A, et al. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
-
(2006)
Am J Transplant
, vol.6
, pp. 459
-
-
Jordan, S.C.1
Vo, A.2
Peng, A.3
-
12
-
-
11144232667
-
Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective
-
Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective. Pediatr Transplant 2004; 8: 535.
-
(2004)
Pediatr Transplant
, vol.8
, pp. 535
-
-
Montgomery, R.A.1
Zachary, A.A.2
-
13
-
-
32544450007
-
Desensitization protocols improving access and outcome in transplantation
-
Zachary AA, Montgomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol 2005; 5: 373.
-
(2005)
Clin Appl Immunol
, vol.5
, pp. 373
-
-
Zachary, A.A.1
Montgomery, R.A.2
Leffell, M.S.3
-
14
-
-
30744475438
-
Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient
-
Crew RJ, Ratner LE. Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient. Semin Dial 2005; 18: 474.
-
(2005)
Semin Dial
, vol.18
, pp. 474
-
-
Crew, R.J.1
Ratner, L.E.2
-
15
-
-
18144419717
-
Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin
-
Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.HumImmunol 2005; 66: 364.
-
(2005)
HumImmunol
, vol.66
, pp. 364
-
-
Zachary, A.A.1
Montgomery, R.A.2
Leffell, M.S.3
-
16
-
-
34247241237
-
14th internationalHLA and immunogenetics workshop: Report on understanding antibodies in transplantation
-
Zachary AA, Montgomery RA, Jordan SC, et al. 14th internationalHLA and immunogenetics workshop: Report on understanding antibodies in transplantation. Tissue Antigens 2007; 69: 160.
-
(2007)
Tissue Antigens
, vol.69
, pp. 160
-
-
Zachary, A.A.1
Montgomery, R.A.2
Jordan, S.C.3
-
17
-
-
56049093677
-
Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy
-
Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
-
(2008)
Transplantation
, vol.86
, pp. 820
-
-
Reinsmoen, N.L.1
Lai, C.H.2
Vo, A.3
-
18
-
-
3042651580
-
Evolution of HLA antibody detection: Technology emulating biology
-
Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41.
-
(2004)
Immunol Res
, vol.29
, pp. 41
-
-
Bray, R.A.1
Nickerson, P.W.2
Kerman, R.H.3
-
19
-
-
4444241202
-
Pronase treatment facilitates alloantibody flow cymetric and cytotoxic crossmatching in the presence of rituximab
-
Bearden CM, Agarwal A, Book BK, et al. Pronase treatment facilitates alloantibody flow cymetric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004; 65: 803.
-
(2004)
Hum Immunol
, vol.65
, pp. 803
-
-
Bearden, C.M.1
Agarwal, A.2
Book, B.K.3
-
20
-
-
0028127304
-
Phase i clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
-
Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457.
-
(1994)
Blood
, vol.84
, pp. 2457
-
-
Maloney, D.G.1
Liles, T.M.2
Czerwinski, D.K.3
-
21
-
-
12844251978
-
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
-
Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55.
-
(2004)
Hum Antibodies
, vol.13
, pp. 55
-
-
Sidner, R.A.1
Book, B.K.2
Agarwal, A.3
-
22
-
-
0000524707
-
The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non- Hodgkin's lymphoma (NHL) cell lines
-
Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non- Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88(suppl 1): 637.
-
(1996)
Blood
, vol.88
, Issue.SUPPL. 1
, pp. 637
-
-
Maloney, D.G.1
Smith, B.2
Appelbaum, F.R.3
-
23
-
-
0037306893
-
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
-
Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949.
-
(2003)
Blood
, vol.101
, pp. 949
-
-
Manches, O.1
Lui, G.2
Chaperot, L.3
-
24
-
-
33846185024
-
The effect of desensitization protocols on human splenic B-cell population in vivo
-
Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell population in vivo. Am J Transplant 2007; 7: 402.
-
(2007)
Am J Transplant
, vol.7
, pp. 402
-
-
Ramos, E.J.1
Pollinger, H.S.2
Stegall, M.D.3
-
25
-
-
20344398005
-
B-cell development: The hematopoietic hierarchy and B-lineage commitment
-
Hoffman, ed., Churchill Livingstone Elsevier, Philadelphia
-
Dorshkind K, Rawlings DJ. B-cell development: The hematopoietic hierarchy and B-lineage commitment. In: Hoffman, ed. Hematology: Basic principles and practice, [ed. 4]. Churchill Livingstone Elsevier, Philadelphia 2005.
-
(2005)
Hematology: Basic Principles and Practice, [Ed. 4]
-
-
Dorshkind, K.1
Rawlings, D.J.2
-
26
-
-
79959664245
-
Better dynamic antibody detection range using flow single antigen assay than Luminex single antigen assay
-
Lai CH, Okhovat J, Ong G, et al. Better dynamic antibody detection range using flow single antigen assay than Luminex single antigen assay. Hum Immunol 2010; 71: S62.
-
(2010)
Hum Immunol
, vol.71
-
-
Lai, C.H.1
Okhovat, J.2
Ong, G.3
|